[go: up one dir, main page]

NZ607408A - Aerosol fluoroquinolone formulations for improved pharmacokinetics - Google Patents

Aerosol fluoroquinolone formulations for improved pharmacokinetics

Info

Publication number
NZ607408A
NZ607408A NZ607408A NZ60740809A NZ607408A NZ 607408 A NZ607408 A NZ 607408A NZ 607408 A NZ607408 A NZ 607408A NZ 60740809 A NZ60740809 A NZ 60740809A NZ 607408 A NZ607408 A NZ 607408A
Authority
NZ
New Zealand
Prior art keywords
improved pharmacokinetics
divalent
present disclosure
aerosol
disclosure relates
Prior art date
Application number
NZ607408A
Inventor
David C Griffith
Michael N Dudley
Olga Rodny
Mark W Surber
Keith A Bostian
Original Assignee
Mpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mpex Pharmaceuticals Inc filed Critical Mpex Pharmaceuticals Inc
Priority to NZ631469A priority Critical patent/NZ631469A/en
Publication of NZ607408A publication Critical patent/NZ607408A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure relates to the field of antimicrobial agents. In particular, the present disclosure relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract. In particular s solution suitable for aerosol and intended for once or twice daily administration that has both: a divalent or trivalent cation concentration from about 50 mM to about 400 mM; and a levofloxacin or ofloxacin concentration from between about 50 mg/ml to about 200 mg/ml.
NZ607408A 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics NZ607408A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ631469A NZ631469A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10350108P 2008-10-07 2008-10-07
NZ592717A NZ592717A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation

Publications (1)

Publication Number Publication Date
NZ607408A true NZ607408A (en) 2014-10-31

Family

ID=41395991

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ592717A NZ592717A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
NZ631469A NZ631469A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics
NZ607408A NZ607408A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics
NZ719761A NZ719761A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ592717A NZ592717A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
NZ631469A NZ631469A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ719761A NZ719761A (en) 2008-10-07 2009-10-06 Aerosol fluoroquinolone formulations for improved pharmacokinetics

Country Status (24)

Country Link
US (6) US8815838B2 (en)
EP (1) EP2344129B1 (en)
JP (3) JP2012505223A (en)
KR (3) KR20160150110A (en)
CN (2) CN102202649A (en)
AU (1) AU2009302478B2 (en)
BR (1) BRPI0920026B1 (en)
CA (1) CA2739897C (en)
CY (1) CY1120140T1 (en)
DK (1) DK2344129T3 (en)
ES (1) ES2666230T3 (en)
HR (1) HRP20180600T1 (en)
HU (1) HUE038428T2 (en)
IL (1) IL212190A (en)
LT (1) LT2344129T (en)
MX (1) MX345158B (en)
NO (1) NO2344129T3 (en)
NZ (4) NZ592717A (en)
PL (1) PL2344129T3 (en)
PT (1) PT2344129T (en)
SG (1) SG194406A1 (en)
SI (1) SI2344129T1 (en)
WO (1) WO2010042553A1 (en)
ZA (1) ZA201103339B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3345895T3 (en) 2003-04-11 2020-05-18 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
SI3219705T1 (en) 2005-12-28 2020-08-31 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
RU2535056C2 (en) 2009-04-24 2014-12-10 Мпекс Фармасьютикалс, Инк. Methods of treating pulmonary bacterial infection with application of fluoroquinolones
EP2467138A4 (en) * 2009-08-19 2013-11-06 Mpex Pharmaceuticals Inc Use of aerosolized antibiotics for treating chronic obstructive pulmonary disease
AU2015275224C1 (en) * 2009-09-04 2017-11-16 Horizon Therapeutics U.S. Holding Llc Use of aerosolized levofloxacin for treating cystic fibrosis
PT2473170T (en) * 2009-09-04 2019-08-23 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
CN103717231B (en) * 2011-05-19 2016-08-17 萨瓦拉股份有限公司 Dry powder vancomycin composition and associated method
KR102045723B1 (en) 2011-09-14 2019-11-18 시오노기 앤드 컴파니, 리미티드 Pharmaceutical composition for inhalation
JP6501264B2 (en) * 2012-07-24 2019-04-17 アヴァリン ファーマ インク． Compounds of analogues of pirfenidone and pyridone in aerosols and their use
WO2015036552A1 (en) * 2013-09-12 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of cystic fibrosis
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP2896400A1 (en) 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
ES2702288T3 (en) 2014-10-07 2019-02-28 Vertex Pharma Co-crystals of transmembrane conductance regulator modulators of cystic fibrosis
US20160108406A1 (en) * 2014-10-08 2016-04-21 University Of Iowa Research Foundation Method of regulating cftr expression and processing
CA3003132A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy
CN109486739B (en) * 2018-11-23 2022-02-01 上海海洋大学 Method for inducing vibrio parahaemolyticus to generate levofloxacin drug resistance
CN109742110B (en) * 2019-01-04 2022-07-08 京东方科技集团股份有限公司 Organic light emitting display and method of manufacturing the same
CN110141569B (en) * 2019-06-13 2021-09-24 吉林大学 Pharmaceutical composition against Pasteurella multocida

Family Cites Families (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US696219A (en) 1901-08-23 1902-03-25 Paul Willemain Building containing acetylene-gas-generating apparatus.
US2587215A (en) 1949-04-27 1952-02-26 Frank P Priestly Inhalator
BE555319A (en) 1956-03-21 1900-01-01
US2858691A (en) 1956-09-04 1958-11-04 Mosler Lock Company Key changed tumbler clamp
BE556587A (en) 1957-01-31 1957-04-11
GB901107A (en) 1959-06-29 1962-07-11 Pfizer Therapeutic composition and method of preparing same
US3669113A (en) 1966-03-07 1972-06-13 Fisons Ltd Inhalation device
US3507277A (en) 1966-09-17 1970-04-21 Fisons Pharmaceuticals Ltd Inhalation device
US3456645A (en) 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
US3456646A (en) 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
US3456644A (en) 1967-01-19 1969-07-22 Dart Ind Inc Inhalation-actuated aerosol dispensing device
GB1268051A (en) 1968-06-07 1972-03-22 Fisons Pharmaceuticals Ltd Inhalation device
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US3636949A (en) 1969-08-08 1972-01-25 Armstrong Kropp Dev Corp Inhalation-initiated aerosol dispenser
BE758834A (en) 1969-11-13 1971-05-12 Riker Laboratoires Inc AEROSOL DISPENSER ACTIVATED BY INHALATION
GB1383761A (en) 1971-02-25 1974-02-12 Woodcraft Dc Inhalation device for use with an aerosol container
US3732864A (en) 1971-06-07 1973-05-15 Schering Corp Inhalation coordinated aerosol dispensing device
IT941426B (en) 1971-07-17 1973-03-01 Isf Spa SWIRL-CHAMBER INHALER FOR POWDER-SHAPING MEDICINAL SUBSTANCES
US3826255A (en) 1972-06-22 1974-07-30 Hudson Oxygen Therapy Sales Co Intermittent positive pressure breathing manifold
FR2224175B1 (en) 1973-04-04 1978-04-14 Isf Spa
IT1016489B (en) 1974-03-18 1977-05-30 Isf Spa INHALER
US3971377A (en) 1974-06-10 1976-07-27 Alza Corporation Medicament dispensing process for inhalation therapy
IT1017153B (en) 1974-07-15 1977-07-20 Isf Spa APPARATUS FOR INHALATIONS
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
SU628930A1 (en) 1974-11-26 1978-10-25 Московский научно-исследовательский институт туберкулеза Device for introducing medicinal powders
US3948264A (en) 1975-05-21 1976-04-06 Mead Johnson & Company Inhalation device
US4147166A (en) 1977-05-02 1979-04-03 American Cyanamid Company Oral inhalator powder dispenser
US4268460A (en) 1977-12-12 1981-05-19 Warner-Lambert Company Nebulizer
US4253468A (en) 1978-08-14 1981-03-03 Steven Lehmbeck Nebulizer attachment
US4263907A (en) 1979-05-14 1981-04-28 Lindsey Joseph W Respirator nebulizer
BR8007911A (en) 1979-12-06 1981-06-16 Glaxo Group Ltd PERFECTED INHALER
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
SE438261B (en) 1981-07-08 1985-04-15 Draco Ab USE IN A DOSHALATOR OF A PERFORED MEMBRANE
US4688218A (en) 1981-07-15 1987-08-18 Etablissement Public De Diffusion Dit "Telediffusion De France" Multiplex channels for continuous flow for numerical signal
US4470412A (en) 1982-03-19 1984-09-11 Trutek Research, Inc. Inhalation valve
US4510929A (en) 1982-04-30 1985-04-16 Bordoni Maurice E Disposable radioactive aerosol inhalation apparatus
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
US4994599A (en) 1987-11-20 1991-02-19 Abbott Laboratories Intermediates for producing quinolone-3-carboxylic acids
US4649911A (en) 1983-09-08 1987-03-17 Baylor College Of Medicine Small particle aerosol generator for treatment of respiratory disease including the lungs
GB8328808D0 (en) 1983-10-28 1983-11-30 Riker Laboratories Inc Inhalation responsive dispensers
JPS60202822A (en) 1984-03-28 1985-10-14 Dai Ichi Seiyaku Co Ltd Antiviral agent
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4648393A (en) 1984-11-02 1987-03-10 Ackrad Laboratories, Inc. Breath activated medication spray
FR2575678B1 (en) 1985-01-04 1988-06-03 Saint Gobain Vitrage PNEUMATIC POWDER EJECTOR
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
NO166131C (en) 1985-06-20 1991-06-05 Daiichi Seiyaku Co ANALOGUE PROCEDURE FOR THE PREPARATION OF S (-) - PYRIDOBENZOKSAZINE COMPOUNDS.
NL8601949A (en) 1985-07-30 1987-02-16 Glaxo Group Ltd DEVICES FOR DELIVERING MEDICAMENTS TO PATIENTS.
US4977154A (en) 1985-12-12 1990-12-11 Warner-Lambert Company 5-amino and 5-hydroxy-6-fluoroquinolones as antibacterial agents
US4809692A (en) 1986-01-31 1989-03-07 Trudell Medical Pediatric asthmatic medication inhaler
IT1204826B (en) 1986-03-04 1989-03-10 Chiesi Farma Spa INHALATION PHARMACEUTICAL COMPOSITIONS
US4790305A (en) 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
US4926852B1 (en) 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
JPS63188627A (en) 1987-01-31 1988-08-04 Rooto Seiyaku Kk Antiallergic and antiphlogistic agents
DE3704907A1 (en) 1987-02-17 1988-08-25 Bayer Ag TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS
US5119806A (en) 1987-05-12 1992-06-09 Glaxo Inc. Inhalation device
KR910000142B1 (en) 1987-05-29 1991-01-21 니혼 다바고 상교오 가부시기가이샤 Filter for cigarette
WO1989000576A1 (en) 1987-07-09 1989-01-26 Pfizer Inc. Azithromycin dihydrate
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4907538A (en) 1988-05-09 1990-03-13 Little Suamico Products Inc. Multiple bin cow feeder
US4832015A (en) 1988-05-19 1989-05-23 Trudell Medical Pediatric asthmatic inhaler
IT1217890B (en) 1988-06-22 1990-03-30 Chiesi Farma Spa DOSED AEROSOL INHALATION DEVICE
FR2636716B1 (en) 1988-09-21 1990-12-07 Staubli Sa Ets DEVICE FOR COUPLING ELEMENT HOLDER PLATES OF MULTIPLE FITTINGS
ATE104867T1 (en) 1988-10-04 1994-05-15 Univ Johns Hopkins INHALATION DEVICE FOR AEROSOLS.
DK479189D0 (en) 1989-01-06 1989-09-28 Hans Gernot Schenk INHALER
US5012803A (en) 1989-03-06 1991-05-07 Trudell Medical Modular medication inhaler
US5012804A (en) 1989-03-06 1991-05-07 Trudell Medical Medication inhaler with adult mask
GB8908647D0 (en) 1989-04-17 1989-06-01 Glaxo Group Ltd Device
EP0470154B1 (en) 1989-04-28 1996-06-05 Riker Laboratories, Inc. Dry powder inhalation device
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
IT1237118B (en) 1989-10-27 1993-05-18 Miat Spa MULTI-DOSE INHALER FOR POWDER DRUGS.
EP0507851B1 (en) 1989-12-29 1997-04-02 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5113855A (en) 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
GB9015077D0 (en) 1990-07-09 1990-08-29 Riker Laboratories Inc Inhaler
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
IT1243344B (en) 1990-07-16 1994-06-10 Promo Pack Sa MULTI-DOSE INHALER FOR POWDER MEDICATIONS
US5060643A (en) 1990-08-07 1991-10-29 Tenax Corporation Breath-activated inhalation device
FR2665635A1 (en) 1990-08-10 1992-02-14 Merck Sharp & Dohme FLUID PHARMACEUTICAL COMPOSITION BASED ON METAL COMPLEX AND PROCESS FOR PREPARING THE SAME.
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5258528A (en) 1990-11-30 1993-11-02 Warner-Lambert Company Individual stereoisomers of pyrrolidine methanamines substituted on the ring nitrogen by a 1-phenylethyl group
US5217004A (en) 1990-12-13 1993-06-08 Tenax Corporation Inhalation actuated dispensing apparatus
US5040527A (en) 1990-12-18 1991-08-20 Healthscan Products Inc. Metered dose inhalation unit with slide means
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5164740A (en) 1991-04-24 1992-11-17 Yehuda Ivri High frequency printing mechanism
AU651882B2 (en) 1991-05-14 1994-08-04 Visiomed Group Limited Aerosol inhalation device
DE69208660T2 (en) 1991-06-10 1996-07-11 Schering Corp., Kenilworth, N.J. FLUORINE CHLORINE HYDROGEN-FREE AEROSOL FORMULATIONS
ATE189124T1 (en) 1991-07-02 2000-02-15 Inhale Inc METHOD AND DEVICE FOR DELIVERING MEDICATIONS IN AEROSOL FORM
IT1250691B (en) 1991-07-22 1995-04-21 Giancarlo Santus THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC.
DE59108798D1 (en) 1991-11-07 1997-08-28 Ritzau Pari Werk Gmbh Paul Nebulizers, in particular for use in devices for inhalation therapy
DE4140689B4 (en) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
DE4142238A1 (en) 1991-12-20 1993-06-24 Boehringer Ingelheim Kg POWDER INHALATOR WITH POWDER SUPPORT FROM REGULAR MICROSTRUCTURES
DK0642366T3 (en) 1992-05-29 1998-07-20 Ggu Ges F R Gesundheits Und Um Apparatus for producing inhalable active particles
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
EG20543A (en) 1992-10-30 1999-07-31 Procter & Gamble Process for preparing of novel antimicrobial -5- (n-heterosubstituted amino) quinolones
NZ250105A (en) 1992-11-09 1996-07-26 Monaghan Canadian Ltd Inhalator mask; one-way valve opens upon exhalation
DK0674533T3 (en) 1992-12-18 1999-09-27 Schering Corp Powdered Inhaler
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
US5532239A (en) 1993-08-02 1996-07-02 Assistance Publique - Hopitaux De Paris Therapeutic application of fluoroquinolone derivatives
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5404781A (en) 1994-06-09 1995-04-11 Ko Shin Electric And Machinery Co., Ltd. Anti-sway means for a saw web
US5642730A (en) 1994-06-17 1997-07-01 Trudell Medical Limited Catheter system for delivery of aerosolized medicine for use with pressurized propellant canister
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US6427682B1 (en) 1995-04-05 2002-08-06 Aerogen, Inc. Methods and apparatus for aerosolizing a substance
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5921237A (en) 1995-04-24 1999-07-13 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6672304B1 (en) 1995-06-08 2004-01-06 Innovative Devices, Llc Inhalation actuated device for use with metered dose inhalers (MDIs)
CN1181896C (en) 1995-06-21 2004-12-29 索福泰克两合公司 Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
CA2176298C (en) 1995-06-27 2009-01-27 Dennis D. Copeland A single high dose fluoroquinolone treatment
AUPN417395A0 (en) 1995-07-14 1995-08-10 Techbase Pty. Ltd. An improved spacer
JP5042447B2 (en) 1995-07-21 2012-10-03 第一三共株式会社 Mixed preparation
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6209538B1 (en) 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
SE9502799D0 (en) 1995-08-10 1995-08-10 Astra Ab Device in inhalers
JP3416145B2 (en) 1995-12-21 2003-06-16 ファイザー インク． Quinolone preparations for injection
US6026809A (en) 1996-01-25 2000-02-22 Microdose Technologies, Inc. Inhalation device
US5694920A (en) 1996-01-25 1997-12-09 Abrams; Andrew L. Inhalation device
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
FR2747311B1 (en) 1996-04-10 1998-08-14 Pf Medicament POWDER AND COMPRESSED AIR INHALER
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6838552B1 (en) 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
CA2227314A1 (en) 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6006747A (en) 1997-03-20 1999-12-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6756369B2 (en) 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6884784B1 (en) 1997-05-06 2005-04-26 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6664239B2 (en) 1997-05-06 2003-12-16 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US6293279B1 (en) 1997-09-26 2001-09-25 Trudell Medical International Aerosol medication delivery apparatus and system
US20030082107A1 (en) 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
HUP0003917A3 (en) 1997-10-08 2001-04-28 Sepracor Inc Marlborough Dosage form for aerosol administration of water-sensitive medicaments
US6003512A (en) 1997-11-13 1999-12-21 Lovelace Respiratory Research Institute Dust gun-aerosol generator and generation
DK1129741T3 (en) 1997-11-19 2006-08-07 Microflow Eng Sa Inhaler atomizer
ID21415A (en) 1997-12-05 1999-06-10 Upjohn Co QUINOLON MAGNESIUM ANTIBIOTIC COMPOUNDS
US6192876B1 (en) 1997-12-12 2001-02-27 Astra Aktiebolag Inhalation apparatus and method
US6223746B1 (en) 1998-02-12 2001-05-01 Iep Pharmaceutical Devices Inc. Metered dose inhaler pump
US6026807A (en) 1998-02-27 2000-02-22 Diemolding Corporation Metered dose inhaler cloud chamber
GB9810299D0 (en) 1998-05-15 1998-07-15 Glaxo Group Ltd Use of nitric oxide synthase inhibitors
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
JP4570251B2 (en) 1998-07-24 2010-10-27 ヤゴテック アーゲー Pharmaceutical aerosol formulation
TW537895B (en) 1998-08-21 2003-06-21 Senju Pharma Co Aqueous solution preparation containing gatifloxacin
ATE322280T1 (en) 1998-09-25 2006-04-15 Cubist Pharm Inc USE OF DAPTOMYCIN
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
GB2343122B (en) 1998-10-26 2003-01-08 Medic Aid Ltd Improvements in and relating to nebulisers
US6070575A (en) 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
US6584971B1 (en) 1999-01-04 2003-07-01 Medic-Aid Limited Drug delivery apparatus
US6350199B1 (en) 1999-03-16 2002-02-26 International Game Technology Interactive gaming machine and method with customized game screen presentation
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6338443B1 (en) 1999-06-18 2002-01-15 Mercury Enterprises, Inc. High efficiency medical nebulizer
CA2282066C (en) 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
EP1223915B1 (en) 1999-10-29 2005-12-21 Nektar Therapeutics Dry powder compositions having improved dispersivity
US6294178B1 (en) 1999-11-01 2001-09-25 Robert E. Weinstein Method and device for coordinating topical and oral sinusitis treatments
CA2386822A1 (en) 1999-11-01 2001-05-10 Alcon, Inc. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
US20010049366A1 (en) 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
CA2826724C (en) 2000-04-11 2016-02-02 Trudell Medical International Aerosol delivery apparatus with positive expiratory pressure capacity
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US6716819B2 (en) 2000-05-19 2004-04-06 University Of Iowa Research Foundation Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections
PE20020044A1 (en) 2000-06-16 2002-01-30 Upjohn Co THIAZINE OXAZOLIDINONE
US6492328B2 (en) 2000-06-28 2002-12-10 The University Of Iowa Research Foundation Novispirins: antimicrobial peptides
AU2001278864A1 (en) 2000-06-30 2002-01-30 University Of Cincinnati Peptides with antioxidant and antimicrobial properties
US6503953B2 (en) 2000-07-26 2003-01-07 Atopic Pty Ltd. Methods for treating atopic disorders
AU2001286852A1 (en) 2000-08-29 2002-03-13 Chiron Corporation Quinoline antibacterial compounds and methods of use thereof
AU2001290239A1 (en) 2000-09-19 2002-04-02 Daiichi Pharmaceutical Co., Ltd. Medicinal composition
US6298656B1 (en) 2000-09-29 2001-10-09 Siemens Westinghouse Power Corporation Compressed air steam generator for cooling combustion turbine transition section
US6601581B1 (en) 2000-11-01 2003-08-05 Advanced Medical Applications, Inc. Method and device for ultrasound drug delivery
JP2004518677A (en) 2000-12-21 2004-06-24 ファルマシア・アンド・アップジョン・カンパニー Antibacterial quinolone derivatives and their use to treat bacterial infections
US6626173B2 (en) 2001-01-08 2003-09-30 Iep Pharmaceutical Devices Inc. Dry powder inhaler
JP2004535370A (en) 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Liquid pharmaceutical composition with masked taste
US6523536B2 (en) 2001-03-12 2003-02-25 Birdsong Medical Devices, Inc. Dual-canister inhaler having a spacer and easy to operate lever mechanism
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6589955B2 (en) 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
ES2222294T3 (en) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. OPTIMIZED FORMULATION OF TOBRAMYCIN FOR ADMINISTRATION IN THE FORM OF AEROSOL.
WO2003035030A1 (en) 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
AU2002364562A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
US20030143265A1 (en) 2001-12-19 2003-07-31 Seiichi Araki Method for treatment of sepsis
US20030171340A1 (en) 2002-02-07 2003-09-11 Jenefir Isbister Methods of disease treatment using metal-complexed tetracycline antibiotics
AU2003230600B2 (en) 2002-03-05 2009-06-04 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
EP1484061A4 (en) 2002-03-11 2009-12-23 Eisai R&D Man Co Ltd Drugs containing riboflavin-type compounds
JP4290381B2 (en) 2002-04-11 2009-07-01 学校法人 聖マリアンナ医科大学 Emulsion containing pyridonecarboxylic acid compound
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CA2483914A1 (en) 2002-05-07 2003-11-20 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
US7423153B2 (en) 2002-05-10 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of gatifloxacin
US20040045546A1 (en) 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
US20040152701A1 (en) 2002-12-02 2004-08-05 Dr. Reddy's Laboratories Limited Novel anhydrous crystalline form of Levofloxacin and process for preparation there of
AU2003285625A1 (en) 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited Pure levofloxacin hemihydrate and processes for preparation thereof
CA2512672A1 (en) 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Methods of treating lung diseases
SI1594500T1 (en) 2003-02-10 2011-02-28 Bayer Schering Pharma Ag Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones
US20060258677A1 (en) 2003-02-15 2006-11-16 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin and processes for preparation
ATE382338T1 (en) 2003-03-19 2008-01-15 Jordanian Pharmaceutical Mfg NON-HYGROSCOPIC PHARMACEUTICAL COMPOSITIONS CONTAINING NON-HYDRATED QUINOLONE CARBONIC ACID
DE10318235A1 (en) 2003-04-22 2004-11-11 Clariant Gmbh Easily dispersible pigments with rapid color strength development
US20070248693A1 (en) 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
SE0302665D0 (en) 2003-10-07 2003-10-07 Astrazeneca Ab Novel Process
CN1312076C (en) 2003-10-14 2007-04-25 长沙理工大学 Ceramic glass pigment produced by using ferrochrome alloy as raw material and production method thereof
AU2004281532B2 (en) 2003-10-15 2010-03-18 Pari Pharma Gmbh Liquid preparation containing tobramycin
DE602004021279D1 (en) 2003-11-17 2009-07-09 Nektar Therapeutics INTRODUCTION OF AEROSOL IN A VENTILATOR CIRCUIT
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
EP1732527A2 (en) 2004-03-17 2006-12-20 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
US7148404B2 (en) 2004-05-04 2006-12-12 Novozymes A/S Antimicrobial polypeptides
AU2005245962A1 (en) 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
US7632869B2 (en) 2004-05-24 2009-12-15 Bausch & Lomb Incorporated Antimicrobial compositions and uses thereof
WO2006002140A2 (en) 2004-06-21 2006-01-05 Nektar Therapeutics Compositions comprising amphotericin b
MX2007000759A (en) 2004-07-22 2007-03-28 Pfizer Prod Inc Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form.
WO2006033713A2 (en) 2004-08-09 2006-03-30 Chiron Corporation Methods for ciprofloxacin inhalation
US7388077B2 (en) 2004-11-12 2008-06-17 Novozymes A/S Polypeptides having antimicrobial activity and polynucleotides encoding the same
CA2595486A1 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
CN103919732A (en) 2005-01-21 2014-07-16 沃纳奇尔科特有限责任公司 A Tetracycline Metal Complex In A Solid Dosage Form
KR20140065482A (en) 2005-03-24 2014-05-29 다이이찌 산쿄 가부시키가이샤 Pharmaceutical composition
US20060286574A1 (en) 2005-04-05 2006-12-21 The Scripps Research Institute & Achaogen, Inc. Compositions and methods for enhancing drug sensitivity and treating drug resistant infections and diseases
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
NZ563417A (en) 2005-05-18 2012-01-12 Mpex Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
BRPI0612602A2 (en) 2005-07-01 2010-11-23 Cinv Ag medical devices comprising a crosslinked composite material
AU2006326456A1 (en) 2005-12-14 2007-06-21 Activbiotics Pharma Llc Rifamycin analogs and uses thereof
WO2007085057A1 (en) 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070248581A1 (en) 2006-01-30 2007-10-25 The University Of Chicago Mgra is a redox regulator of antibiotic sensitivity and virulence
LT1991201T (en) 2006-02-10 2018-07-25 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
CA2642754A1 (en) 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
ATE446946T1 (en) 2006-06-27 2009-11-15 Sandoz Ag NEW PROCESS FOR PRODUCING SALT
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
GB0719248D0 (en) 2007-10-03 2007-11-14 Generics Uk Ltd Compounds and methods for pharmaceutical use
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20090197212A1 (en) 2008-02-04 2009-08-06 Maxitrol Company Premix Burner Control System and Method
BRPI0913021A2 (en) 2008-05-15 2015-10-13 Novartis Ag pulmonary distribution of a fluoroquinolone
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
RU2535056C2 (en) 2009-04-24 2014-12-10 Мпекс Фармасьютикалс, Инк. Methods of treating pulmonary bacterial infection with application of fluoroquinolones
CA2770341A1 (en) * 2009-08-19 2011-02-24 Mpex Pharmaceuticals, Inc. Riboflavin based aerosol and use as placebo in trials
EP2467138A4 (en) * 2009-08-19 2013-11-06 Mpex Pharmaceuticals Inc Use of aerosolized antibiotics for treating chronic obstructive pulmonary disease
PT2473170T (en) * 2009-09-04 2019-08-23 Horizon Orphan Llc Use of aerosolized levofloxacin for treating cystic fibrosis
US20150299122A1 (en) 2012-08-31 2015-10-22 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
MX2018001315A (en) 2015-07-30 2018-08-15 Horizon Orphan Llc Fucosidase inhibitors.

Also Published As

Publication number Publication date
ZA201103339B (en) 2012-04-18
NO2344129T3 (en) 2018-07-21
US20100087416A1 (en) 2010-04-08
HRP20180600T1 (en) 2018-06-01
NZ631469A (en) 2016-06-24
ES2666230T3 (en) 2018-05-03
NZ592717A (en) 2013-03-28
IL212190A0 (en) 2011-06-30
CA2739897A1 (en) 2010-04-15
US20190321371A1 (en) 2019-10-24
BRPI0920026B1 (en) 2023-11-07
US20160287606A1 (en) 2016-10-06
DK2344129T3 (en) 2018-05-07
US20180104252A1 (en) 2018-04-19
JP2015120751A (en) 2015-07-02
KR20160150110A (en) 2016-12-28
US8815838B2 (en) 2014-08-26
IL212190A (en) 2017-03-30
US9717738B2 (en) 2017-08-01
SG194406A1 (en) 2013-11-29
CY1120140T1 (en) 2018-12-12
AU2009302478A1 (en) 2010-04-15
AU2009302478B2 (en) 2015-09-03
BRPI0920026A2 (en) 2015-12-15
MX2011003745A (en) 2011-06-09
CN102202649A (en) 2011-09-28
PT2344129T (en) 2018-04-23
KR20180001572A (en) 2018-01-04
EP2344129A1 (en) 2011-07-20
KR20110091510A (en) 2011-08-11
EP2344129B1 (en) 2018-02-21
MX345158B (en) 2017-01-18
US9326936B2 (en) 2016-05-03
CA2739897C (en) 2017-10-03
US20210121472A1 (en) 2021-04-29
US10722519B2 (en) 2020-07-28
JP2017002089A (en) 2017-01-05
US10149854B2 (en) 2018-12-11
SI2344129T1 (en) 2018-06-29
WO2010042553A1 (en) 2010-04-15
NZ719761A (en) 2017-11-24
US20140329810A1 (en) 2014-11-06
JP2012505223A (en) 2012-03-01
HUE038428T2 (en) 2018-10-29
KR101959873B1 (en) 2019-03-19
PL2344129T3 (en) 2018-07-31
CN105520922A (en) 2016-04-27
LT2344129T (en) 2018-05-10
JP6067047B2 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
NZ607408A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
MX359219B (en) Aerosolized fluoroquinolones and uses thereof.
WO2007095156A3 (en) Taste masking of aerosolized fluoroquinolones
MX2012002731A (en) Use of aerosolized levofloxacin for treating cystic fibrosis.
UA94901C2 (en) Antibacterial piperidine derivatives
MX2009005603A (en) Antibacterial polycyclic urea compounds.
IL215275A0 (en) Pharmaceutical formulations and methods for treating respiratory tract infections
BR112013028813A2 (en) 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
BR112013032974A2 (en) "1,6-diazabicyclo [3,2,1] -octan-7-one derivatives, their uses, and pharmaceutical compositions".
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
BR112013029246A2 (en) 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazol-2-yl] -1h-quinolin-2-one for use in the treatment of adenoid cystic carcinoma
MX2008016134A (en) Phenol derivatives for the treatment of respiratory diseases.
WO2007071965A3 (en) Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
MX336260B (en) Treatment of lung infections by administration of tobramycin by aerolisation.
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
GB0722077D0 (en) Compounds
MX346244B (en) Dry powder vancomycin compositions and associated methods.
WO2010047737A3 (en) Antimicrobial indoline compounds for treatment of bacterial infections
MX2009006325A (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents.
PL1610787T3 (en) Synergistic combination comprising roflumilast and an anticholinergic agent selected from tiotropium salts for the treatment of respiratory diseases
MY144714A (en) Treatment of bacterial diseases of the respiratory organs
MX2010001403A (en) Topical composition containing the combination of mupirocin and beclomethasone.
WO2009077485A3 (en) 1(2)h-tetrazol-5-yl-phenyl-oxazolidinones as antibacterial agents
WO2007130743A3 (en) Capreomycin derivatives and their use as antibacterials

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 OCT 2016 BY AJ PARK

Effective date: 20150409

ASS Change of ownership

Owner name: RAPTOR PHARMACEUTICALS, INC., US

Effective date: 20160310

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2017 BY COMPUTER PACKAGES INC

Effective date: 20160920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2018 BY CPA GLOBAL

Effective date: 20170921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2019 BY COMPUTER PACKAGES INC

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2020 BY COMPUTER PACKAGES INC

Effective date: 20190918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20200918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2022 BY COMPUTER PACKAGES INC

Effective date: 20210917

LAPS Patent lapsed